Ritonavir is a cytochrome P450 3A inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection, among other approved uses. It is available as tablets and oral powder. MedsAcross supplies Ritonavir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
NORVIR tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. NORVIR oral powder is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with HIV-1 infection. NORVIR tablets are HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Source: US FDA prescribing information
Ritonavir is an antiretroviral drug.
Source: US FDA prescribing information
Adult patients: 600 mg twice-day with meals. Pediatrics patients: Do not exceed 600 mg twice daily dose with meals for children greater than one month of age. The dose is based on body surface area. Use NORVIR oral powder only for dosing increments of 100 mg. Follow the Instructions for Use for preparation and administration of NORVIR oral powder. Dose modification for NORVIR is necessary when used with other protease inhibitors
Source: US FDA prescribing information
• Consult the prescribing information of the co-administered protease inhibitor for contraindication information for that product. • NORVIR is contraindicated in patients with known hypersensitivity (e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome) to ritonavir or any of its ingredients.
Source: US FDA prescribing information
Boxed warning (drug-drug interactions leading to potentially serious and/or life threatening reactions): Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism of certain drugs. The following have been observed in patients receiving NORVIR: The concomitant use of NORVIR and certain other drugs may result in known or potentially significant drug interactions. Consult the full prescribing information prior to and during treatment for potential drug interactions. Hepatotoxicity: Fatalities have occurred. Monitor liver function before and during therapy, especially in patients with underlying hepatic disease, including hepatitis B and hepatitis C, or marked transaminase elevations.
Source: US FDA prescribing information
The following adverse reactions are discussed in greater detail in other sections of the labeling. Drug Interactions Hepatotoxicity Pancreatitis Allergic Reactions/Hypersensitivity When co-administering NORVIR with other protease inhibitors, see the full prescribing information for that protease inhibitor including adverse reactions. The most frequently reported adverse drug reactions among patients receiving NORVIR alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower), neurological disturbances (including paresthesia and oral paresthesia), rash, and fatigue/asthenia
Source: US FDA prescribing information
When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy
Source: US FDA prescribing information
Storage Store at or below 30°C (86°F). Exposure to temperatures up to 50°C (122°F) for seven days permitted. Store at or below 30°C (86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Ritonavir, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Ritonavir 100 mg tabletOralGeneric name | — | US FDA | Available on request |
| Norvir 100 mg tabletOral | AbbVie | US FDA | Available on request |
| Norvir 100 mg oral powderOral | AbbVie | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Ritonavir in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Ritonavir and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Ritonavir, including Norvir.
Yes. The US FDA first approved Ritonavir on 1 March 1996, according to Drugs@FDA.
Yes. Ritonavir has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Ritonavir is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Ritonavir is classified under ATC code J05AE03 (Ritonavir).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.